Natural killer cells,at the right moment.

01Our therapy

NOK is developing a genetically unmodified, autologous NK cell therapy.

A repeatable, patient-derived NK cell approach designed to be gentle on the host while targeting residual disease after intense treatment.

Illustration: a patient's own NK cells are collected, expanded by NOK, and returned to the same patient.
Expanded, autologous NK cells

02How it works

Step 1

The patient’s own NK cells.

Prior to starting initial treatment, a small number of NK cells are collected from the patient. No donor.

Step 2a

Intensive treatment comes first.

The patient goes through intensive treatment, such as chemotherapy and a stem cell transplant. It clears most of the cancer, but not always all of it: a few cells can be left behind.

Step 2b

Multiplied two-thousandfold.

Meanwhile, our proprietary method expands these NK cells ~2,000× and turns them into high-quality cancer fighters. No genetic editing required.

Step 3

Quick & simple infusion.

A 10-minute infusion returns them to the same patient, with no preconditioning beforehand.

Step 4

Seek and destroy.

Our NK cells are primed to find and kill cancer cells, targeting the residual disease left behind.

Step 5

Again, and again.

Cells kept back from the same batch go in as repeat doses, keeping up the pressure on any cancer cells that remain.

Why NK cells?

03Why NK cells

So, why NK cells?

Most cell therapies use T cells, often seen as the “stronger” immune cell. So why do we use NK cells?

  1. 01Disease-agnostic killingNK cells recognize and kill stressed and cancerous cells without needing a single predefined target.
  2. 02Killing antibody-coated cellsThey pair naturally with the antibody therapies already used in myeloma, killing the cells those antibodies mark.
  3. 03Sparking an immune responseActivated NK cells release signals that recruit and prime the rest of the immune system.
  4. 04Limited toxicitiesA safety profile that supports repeat dosing, even after intensive treatment.

This makes NK cells the perfect therapeutic to seek out and mop up residual cancer cells following intense treatment.

An NK cell and its four therapeutic properties: disease-agnostic killing, killing antibody-coated cells, sparking an immune response, and limited toxicities. 01020304NKcell

04Our pipeline

From first-in-human data to the next study.

Our lead candidate, evencaleucel, is in post-transplant multiple myeloma: Phase 1 is complete, and we are preparing the next clinical study.

Explore our pipeline